Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 2/20 | 0.35 |
| ▸ | SELP | P16109 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27103105 | 0.81 | IRAK1 (0.37) | PIK3C3 | |
| SCHEMBL27103100 | 0.80 | LRRK2 (0.36) | LRRK2EGFR | |
| SCHEMBL27103106 | 0.72 | PRKCH (0.35) | EGFR | |
| SCHEMBL15263527 | 0.71 | RAF1 (0.38) | LRRK2EGFR | |
| SCHEMBL29699267 | 0.71 | RAF1 (0.38) | LRRK2EGFR | |
| SCHEMBL27103103 | 0.71 | FLT3 (0.39) | TYRO3MERTKPIK3C3EGFR | |
| SCHEMBL24457858 | 0.70 | LRRK2 (0.35) | LRRK2EGFR | |
| SCHEMBL24457853 | 0.70 | FGFR1 (0.40) | EGFR | |
| SCHEMBL22625609 | 0.70 | KRAS (0.31) | — | |
| SCHEMBL22612825 | 0.70 | ULK1 (0.34) | HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | TYRO3 2836/4885SELP 4718/4885AXL 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.